Google
RLMD — RELMADA THERAPEUTICS INC (Healthcare >> Biotechnology)
RLMD FAQ
What is RLMD's ROE?
RELMADA THERAPEUTICS INC reports a Return on Equity (ROE) of -26.92%.
What is RLMD's dividend yield?
RELMADA THERAPEUTICS INC offers a dividend yield of 0.00%.
What is RLMD's Deepscope Quality Score?
Deepscope rates RLMD's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy RLMD?
Deepscope's AI Timing Score for RLMD is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does RLMD belong to?
RELMADA THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 5.95
Price
-0.36
(-5.71%)
Day Change
|
|
|---|
RLMD, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 5.95 |
| PBV / Sector |
2.82 / 4.63
|
| Earning Per Share | -0.57 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
6.98 M
|
| Average 1W Daily Value |
6.96 M
|
| Timing Factors |
|
28% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:09:01 |
| Symbol | RLMD |
| Name | RELMADA THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 104.89 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 616.75 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2222 Ponce de Leon Blvd., Coral Gables, FL, United States, 33134
Phone: 786 629 1376
Website: https://www.relmada.com
Sector: Healthcare >> Biotechnology
Description: Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
